πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 259 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12427212

Nectin-4 binding miniproteins, conjugates and uses thereof

Aktis Oncology, Inc. Β· Granted Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12410184

Crystalline forms of a menin inhibitor

Kura Oncology, Inc. Β· Granted Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12404497

Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof

Medicenna Therapeutics Inc. Β· Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12377115

Combination immunotherapies for treatment of cancer

PrimeVax Immuno-Oncology Β· Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12370229

Methods of treating bladder cancer

CG ONCOLOGY, INC. Β· Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12358976

Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d

Ultragenyx Pharmaceutical Inc. Β· Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12331079

Oncolytic virus platform to treat cancers with myxoma virus

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12263173

PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

Cardiff Oncology, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12194064

Process of producing concentrated therapeutic phospholipid composition from krill extracts

Aker BioMarine Human Ingredients AS Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12162877

Human dihydroorotate dehydrogenase (hDHODH) inhibitors and their use in targeting oncologi

DRUG DISCOVERY AND CLINIC S.R.L. Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12144813

PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

Cardiff Oncology, Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12122837

Oncostatin M receptor antigen binding proteins

Kiniksa Pharmaceuticals, GmbH Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097210

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

Corcept Therapeutics Incorporated Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12090183

Methods of treating solid or lymphatic tumors by combination therapy

CG ONCOLOGY, INC. Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12059443

Method for treating cancer using dengue virus serotype 1 (DENV-1)

PrimeVax Immuno-Oncology Β· Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12036280

High concentration protein formulation

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12018011

Macrocyclic compounds and compositions, and methods of preparing and using the same

Kura Oncology, Inc. Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12005194

Configurable oxygen concentrator and related method

SEPARATION DESIGN GROUP LLC Β· Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11975106

Uses of halogenated xanthenes in oncology and virology

Provectus Pharmatech, Inc. Β· Granted Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11969435

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

Corcept Therapeutics Incorporated Β· Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11957677

Cancer treatment using FGFR inhibitors and PLK1 inhibitors

Cardiff Oncology, Inc. Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11944627

Methods for treating hematological malignancies and Ewing's sarcoma

Kura Oncology, Inc. Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11944617

Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxe

Corcept Therapeutics Incorporated Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11884656

Pyrrole derivatives as PLK1 inhibitors

SENTINEL ONCOLOGY LIMITED Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted